In-Practice Evaluation of Atacand 16mg Antihypertensive Effect

This study has been completed.

First Received: December 4, 2008 Last Updated: June 18, 2009 History of Changes

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00802542

Purpose

The purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure after 4 weeks of administration and the importance of administration of adequate doses

Condition
Essential Hypertension

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	In-Practice Evaluation of Atacand 16mg Antihypertensive Effect

Resource links provided by NLM:

MedlinePlus related topics: Blood Pressure Medicines High Blood Pressure

Drug Information available for: CV 11974 Candesartan cilexetil

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Decrease in blood pressure [ Time Frame: once after 4 weeks ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	400
Study Start Date:	December 2008
Study Completion Date:	February 2009

Groups/Cohorts
1 Adult patients with mild or moderate essential hypertension who do not tolerate ACE inhibitors because of cough, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal and the doctor has decided to increase the Atacand dose to 16mg as per SmPC.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

out-patient departments

Criteria

Inclusion Criteria:

Adult patients with mild (140-159/90-99 mgHg) to moderate (160-179/100-109 mmHg) essential hypertension, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal at least <140/90 mgHg and the doctor has decided
Signed and dated Patient Informed Consent (ICF)

Exclusion Criteria:

Hypersensitivity to the active substance or to any of the excipients of Atacand.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00802542

Locations

Latvia
Research Site
Riga, Latvia
Research site
Liepaja, Latvia
Research site
Daugavpils, Latvia
Research site
Jelgava, Latvia

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

Agrita Hartmane

AstraZeneca

More Information

No publications provided

Responsible Party:	AstraZeneca MC Latvia ( Janis Dobelis )
Study ID Numbers:	NIS-CLV-ATA-2008/1
Study First Received:	December 4, 2008
Last Updated:	June 18, 2009
ClinicalTrials.gov Identifier:	NCT00802542 History of Changes
Health Authority:	Latvia: State Agency of Medicines

Keywords provided by AstraZeneca:

Hypertension
blood pressure
Atacand

Additional relevant MeSH terms:

Angiotensin II Type 1 Receptor Blockers
Candesartan cilexetil
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Vascular Diseases

Cardiovascular Diseases
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions
Hypertension

ClinicalTrials.gov processed this record on February 08, 2010